OBM Transplantation is an international peer-reviewed Open Access journal, which covers all evidence-based scientific studies related to transplantation, including: transplantation procedures and the maintenance of transplanted tissues or organs; assimilation of grafted tissue and the reconstitution of removed organs or parts of organs; transplantation of heart, lung, kidney, liver, pancreatic islets and bone marrow, etc. Areas related to clinical and experimental transplantation are also of interest.
OBM Transplantation is committed to rapid review and publication, and we aim at serving the international transplant community with high accessibility as well as relevant and high quality content.
We welcome original clinical studies as well as basic science, reviews, short reports/rapid communications, case reports, opinions, technical notes, book reviews as well as letters to the editor.
Archiving: full-text archived in CLOCKSS.
Rapid publication: manuscripts are undertaken in 8 days from acceptance to publication (median values for papers published in this journal in 2021, 1-2 days of FREE language polishing time is also included in this period).
Allogenic Stem Cell Transplantation
Submission Deadline: December 15, 2021 (Open) Submit Now
Yvonne A. Efebera, MD, MPH
Professor, Blood and Marrow Transplantation Program, Ohio State University, Columbus, Ohio, USA
Research Interests: Multiple myeloma; graft vs host disease; paraproteinemias; amyloidosis; necrobiotic xanthogranuloma; blood and marrow transplantation
Nidhi Sharma, PhD
Internal Medicine, Division of Hematology, Ohio State University, Columbus, OH, USA
Research Interest: Graft vs host disease (GVHD); allogenic stem cell transplantation; autologous stem cell transplantation; stem cell transplantation
About This Topic
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is increasingly used for patients with hematological malignancies. In particular, allogenic hematopoietic stem cell transplantation (allo-HSCT) is increasingly used for patients with high-risk leukemia’s and refractory lymphomas. The success of this is based on immune-based graft versus leukemia effect caused by donor T cells. Donor T-cells, however, are also the cause of graft versus host disease (GVHD). GVHD remains a leading cause of morbidity and mortality in allogeneic hematopoietic stem marrow transplant (allo-HSCT), with rates ranging from 25% to 68%. In addition, it is often impeded by several factors including relapse of the underlying disease, and infectious complications. Hence, the practice of allo-SCT is continuously evolving to mitigate these factors. In particular, advances in the conditioning regimens, GVHD prophylaxis, infectious disease monitoring and prophylaxis and supportive care not only have resulted in improved outcomes, but also have expanded potential indications for allo-HSCT. Given the rapidly evolving treatment scenario and promising findings, allo-SCT holds the potential for better survival outcomes for patients with hematological malignancies. Here we welcome papers outlining the role and new advancements in allogenic transplantation in the treatment of hematological malignancies.
To prevent robots and page crawlers from submitting fraudulent forms, complete verification to prove that you are a human.